European Biotechnology

Published September 24, 2026

Kasvu raises €30M for depression drug targeting TrkB - European Biotechnology Magazine

Read the full story at European Biotechnology

Why it matters: Kasvu aims to reproduce the neuroplasticity benefits associated with psychedelics without their hallucinogenic effects. · The financing.